Gankang Mixture Combined with Interferon for 54 Cases of Chronic Hepatitis B

JIN Tao; YOU Yun-ge; LI Qing-xiu; et al.

doi:10.13288/j.11-2166/r.2007.03.014

您当前的位置：

首页 >

文章列表页 >

Gankang Mixture Combined with Interferon for 54 Cases of Chronic Hepatitis B

更新时间：2021-11-17

- Gankang Mixture Combined with Interferon for 54 Cases of Chronic Hepatitis B
- Journal of Traditional Chinese Medicine Issue 3, Pages: 220-222(2007)
- 作者机构：
  
  1. 湖南省临澧县中医医院消化内科
  2. 湖南省临澧县中医医院消化内科临澧县安福镇迎宾路29号
  3. ,415200
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2007.03.014
  CLC： R512.62
- Published：2007
- 稿件说明：
移动端阅览
[1]金涛,游运舸,李清秀,吴国军.肝康合剂联合干扰素治疗慢性乙型肝炎54例[J].中医杂志,2007(03):220-222.

JIN Tao, YOU Yun-ge, LI Qing-xiu, et al. Gankang Mixture Combined with Interferon for 54 Cases of Chronic Hepatitis B[J]. Journal of Traditional Chinese Medicine2007, (3): 220-222.
[1]金涛,游运舸,李清秀,吴国军.肝康合剂联合干扰素治疗慢性乙型肝炎54例[J].中医杂志,2007(03):220-222. DOI： 10.13288/j.11-2166/r.2007.03.014.

JIN Tao, YOU Yun-ge, LI Qing-xiu, et al. Gankang Mixture Combined with Interferon for 54 Cases of Chronic Hepatitis B[J]. Journal of Traditional Chinese Medicine2007, (3): 220-222. DOI： 10.13288/j.11-2166/r.2007.03.014.

摘要

目的观察肝康合剂联合干扰素治疗慢性乙型肝炎的临床疗效。方法选择慢性乙型肝炎病例

应用肝康合剂联合干扰素进行治疗

与单独应用肝康合剂和单独应用干扰素治疗的患者进行对比观察

总疗程均为6个月。观察患者治疗前后症状、体征的改善情况及肝功能、病毒标志物的变化情况。结果治疗组及两对照组总有效率分别为94.4%和90.4%、85%

差异无显著性意义（P>0.05）;在肝功能复常方面

3组亦无显著性差异（P>0.05）;在乙型肝炎e抗原（HBeAg）、乙型肝炎病毒基因（HBV-DNA）阴转方面

治疗组明显优于两对照组

差异有显著性意义（P<0.01或P<0.05）。结论肝康合剂联合干扰素治疗慢性乙型肝炎具有较好疗效

肝康合剂能明显提高干扰素的抗病毒疗效。

Abstract

Objective To study the therapeutic effect of Gankang Mixture combined with interferon for chronic hepatitis B（CHB）.Methods CHB patients were treated by Gankang Mixture combined with interferon and compared with those who treated by Gankang Mixture or interferon merely.The treatment lasted for 6 months.Symptoms

signs

hepatic function and hepatitis B virus （HBV） marker were observed before and after treatment.Results The total effective rate of the treatment group and both control groups were 94.4%

90.4% and 85% respectively.There were no significant differences in total effective rate and hepatic function among three groups（P>0.05）.The treatment group was superior to both control groups in negative conversion rate of HBeAg and HBV-DNA （P<0.05 or P<0.01）.Conclusion Gankang Mixture can obviously increase antiviral effect of interferon.Their combination has better therapeutic effect for CHB.

关键词

Keywords

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

The Effect of Fuzheng Huaji Formula （扶正化积方） for Chronic Hepatitis B on Reduction of the Incidence of Liver Cirrhosis and Hepatocellular Carcinoma：A Retrospective Cohort Study

Evolutionary Law of Syndrome and Syndrome Elements during the Malignant Transformation of Chronic Hepatitis B

Effect of Longchai Formula （龙柴方） Drug-containing Serum Combined with Entecavir on P-glycoprotein and PI3K/AKT Signaling Pathway in HepG2.2.15 Hepatocellular Carcinoma Cells

The Effect of Qingre Huashi Formula （清热化湿方） on Chronic Hepatitis B or Nonalcoholic Fatty Liver Disease with Damp-heat Syndrome： a Multicenter Randomized Double-blind Placebo-controlled Trial

Qingfei Paidu Decoction （清肺排毒汤） Combined with Western Medicine Routine Treatment for Coronavirus Disease 2019 （COVID-19） Concomitant with Chronic Hepatitis B： A Multi-center Retrospective Study

Related Author

YU Simiao

LI Jiahui

JING Jing

HE Tingting

SUN Yongqiang

WANG Liping

ZHANG Aozhe

XIAO Xiaohe

Related Institution

School of Traditional Chinese Medicine，Beijing University of Chinese Medicine

Fifth Medical Center，The People's Liberation Army General Hospital

National Institute of TCM Constitution and Preventive Medicine，Beijing University of Chinese Medicine

The Fifth Medical Center of Chinese PLA General Hospital

Dongzhimen Hospital，Beijing University of Chinese Medicine

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰